Bone Health in Children with Duchenne Muscular Dystrophy: A Review

Nadia Perera1 and Michelle Farrar1,2

1Discipline of Pediatrics, The University of New South Wales, Australia
2Department of Neurology, Sydney Children's Hospital, Australia

Corresponding author: Michelle Farrar, Department of Neurology, Sydney Children's Hospital, High St, Randwick, NSW, 2031, Australia, Tel: +61 2 93821549; Fax: +61 2 93821580; E-mail: m.farrar@unsw.edu.au

Keywords: Duchenne muscular dystrophy; Bone health; Osteoporosis; Fracture; Vitamin D

Abstract

Duchenne muscular dystrophy (DMD) patients are vulnerable to osteoporosis and fractures. This has significant impact on the mobility and quality of life of DMD patients, making the development of strategies to prevent or treat these complications critical. As such, this review incorporates a discussion of the determinants of bone health in healthy children, followed by an examination of bone health in DMD, with a particular focus of vitamin D deficiency and its implications. An illustrative case study highlights the bone-related complications that can occur in DMD and assessment approach.

Introduction

Children suffering from neuromuscular disorders such as Duchenne muscular dystrophy (DMD) are vulnerable to poor bone health and osteoporosis, a systemic disease characterised by low bone mass with a consequent increase in fragility and susceptibility to fracture [1]. This has significant implications for the quality of life and mobility of DMD patients, making the development of strategies to prevent or treat these complications critical. As such, this review incorporates a discussion of the determinants, assessment and management of bone health in healthy children followed by an examination of bone health in DMD, with a particular focus on vitamin D deficiency and its implications.

The Biology of Bone Health in Children

Childhood and adolescence are critical periods for the development of peak bone mass, which plays a large role in determining bone strength and later risk of osteoporosis [2,3]. Bone size, bone mineral density (BMD) and bone mineral content (BMC) are increased through the deposition of osteoid and its mineralisation with calcium and phosphate by osteoblasts [4]. Bone simultaneously undergoes resorption by osteoclasts during bone remodelling, which occurs in response to physical stress and endocrine signals [5]. The balance between bone deposition and resorption determines net bone formation; when there is a relative increase in bone resorption there is a decline in BMD, which can lead to weakened osteoporotic bones and an increased risk of fractures.

The Determinants of Bone Health in Children

Studies have established that peak bone density has a high genetic component, with about 70-80% of variability attributable to hereditary factors [6,7]. In addition, hormonal and lifestyle factors play a significant role in determining the bone health of children and adolescents. Understanding these determinants of bone health and the pathophysiological mechanisms contributing to the development of osteoporosis is critical in improving strategies to reduce osteoporosis and fragility fractures long term, and are discussed below.

Endocrine Factors

Numerous hormones have been found to have an influence on bone health in children. The active form of vitamin D, 25-OH vitamin D (25-OHD), serves to enhance absorption of calcium from the intestine and hence promote skeletal mineralization [8]. In addition, parathyroid hormone (PTH) and calcitonin work in concert to regulate serum calcium levels by influencing bone deposition and resorption, as summarised in Figure 1.

The androgen and oestrogen hormones are of substantial importance during puberty. These hormones, particularly oestrogen, stimulate significant bone growth during early puberty and mediate the later closure of the epiphyseal growth-plates and hence peak bone size [9-12]. The timing of puberty consequently has an effect on the peak bone mass achieved, with delayed puberty associated with decreased BMD and BMC in adulthood [13].

Corticosteroids have varied and complex effects on bone health. Endogenous corticosteroids are necessary for the regulation of bone remodelling and differentiation of osteoblasts [5]. However, prolonged exposure to excess corticosteroids as occurs during the treatment of some conditions has negative impacts on bone health. These include the decreasing of bone formation through the suppression of osteoblasts, and the increasing of bone resorption via increased renal excretion and reduced gastrointestinal absorption of calcium; effects which consequently increase the risk of osteoporosis [14].

Nutritional Factors

Adequate levels of nutrients, particularly calcium and vitamin D, are critical for bone development during childhood and adolescence. Increasing dietary calcium, with or without vitamin D, significantly increased BMC in children with low baseline intakes in a recent meta-analysis of 21 randomised controlled trials [15]. Current Australian guidelines recommend that children and adolescents receive a daily...
calcium intake of 500-1300 mg/day to promote adequate bone mineralisation [16].

As previously discussed, calcium absorption also requires adequate vitamin D. Over 80% of vitamin D in Australia is derived from skin exposure to UVB radiation in sunlight, but small amounts of vitamin D can also be found in foods such as oily fish and egg [17]. Both the American Academy of Pediatrics and Australian guidelines currently recommend a daily vitamin D intake of 400 IU [18,19].

Figure 1: The regulation of calcium by parathyroid hormone and vitamin D, and its effects on bone. Vitamin D is ingested or synthesised in the skin via the action of ultraviolet B (UVB) sunlight. It is metabolised by the liver and kidney to form into its active form, 1, 25-dihydroxy vitamin D (1, 25 (OH) 2D), which is critical for calcium absorption in the gut. Serum calcium levels influence parathyroid hormone release, which in turn influences bone resorption or deposition. Bisphosphonates decrease osteoclast activity and hence promote bone formation, whereas corticosteroids negatively impact bone by decreasing calcium absorption and osteoblast activity.

Biochemical Tests

Levels of serum calcium, 25-OH vitamin D (25-OHD) and PTH are routinely measured in assessing bone health. Bone health can also be assessed through biochemical markers of bone turnover, which reflect bone formation and resorption. Challenges are posed in interpreting these tests in children, as there is great variability in normal ranges due that limit sun exposure, such as the wearing of veils or chronic hospitalisation [17,26].

Evaluating Bone Health in Children

Assessing the factors discussed above can help guide management to reduce a child’s risk of osteoporosis and fracture. Various investigations may be undertaken to give an overall understanding of the strength and condition of a child’s bones, which are discussed below.
to changes in skeletal metabolism induced by differences in age, growth rate, gender and maturity [27]. However, these tests can be useful in monitoring responses to treatment and determining underlying bone pathology.

**Dual Energy X-ray Absorptiometry (DXA)**

Dual energy x-ray absorptiometry (DXA) is the standard method used to assess bone mineral mass and density. This technique involves beaming low-intensity radiation through the body and determining BMC based on the degree of attenuation, from which an estimate of BMD can be calculated. While DXA is in widespread use, several issues exist surrounding its interpretation in children. DXA scores are reported as "T-scores" and "Z-scores", which compare an individual's bone density with that of a healthy 30-year-old of the same gender and an average person of the same age and gender respectively. The values are expressed in units of standard deviations. DXA results are affected by bone size, maturity and body composition, with DXA tending to underestimate BMD in small subjects and overestimate BMD in large subject [28]. DXA results must therefore be adjusted based on subject size, but no consensus on the most appropriate correction method has been reached [28].

Another challenge lies in relating DXA to fracture risk in children. This is achieved in adults via the use of T-scores, which are derived by comparing BMC results to healthy young adults at peak bone mass [1]. T-scores cannot however be used in children who have not yet reached peak bone mass, and hence Z-scores, which use age and gender matched reference data for comparison, must be used. Currently, the International Society for Clinical Densitometry defines a size-adjusted BMD Z-score of <-2 as low in children [29]. However, although a clear inverse relationship between BMD Z-scores and risk of fractures has been found in healthy children [30], a precise estimate of fracture risk based on Z-scores in paediatrics is not yet well established.

**Vitamin D Deficiency in Children**

Although controversy exists over the optimum level of Vitamin D and how to define its deficiency, vitamin D deficiency is currently defined in Australia as a serum 25-hydroxyvitamin D (25-OHD) concentration of less than 50 nmol/L (or 20 ng/mL) [31]. This is best measured at the end of winter, when there is the greatest risk of deficiency [25].

Vitamin D deficiency leads to poor calcium absorption, inadequate bone mineralisation and an increased risk of pathological fracture [32], manifesting when severe as rickets or osteomalacia [19]. Vitamin D deficiency rickets has recently emerged as a significant problem in Australian children among known high-risk groups [33], highlighting the necessity for public health management strategies. In addition, vitamin D has been shown to influence the expression of hundreds of genes linked to inflammation, regeneration, autoimmune disorders, malignancies and cardiovascular disease [34,35], and may serve as an epigenetic factor in the progression of diseases such as DMD.

Despite increasing recognition that a significant number of children suffer from vitamin D deficiency, its prevalence is difficult to determine. Studies are complicated by the seasonal variability of vitamin D levels and variable access to sunlight in different locations [16,36,37]. Nevertheless, large population studies in Australia and the US have found the prevalence of vitamin D deficiency in adults to be around 32%-42% [36,38]. While studies on the prevalence of vitamin D deficiency in children within Australia are limited, several studies have been conducted on children internationally (Table 1). These have generally shown that vitamin D deficiency is relatively lower during infancy at about 5.4%-12.1% [37,39], but increases in childhood and adolescence to around the same levels as those seen in adults [37,40,41]. Although many of these studies are limited by their small sample sizes, they demonstrate that vitamin D deficiency is a relatively common and significant health problem in children, highlighting the importance of developing further understanding of the pathophysiological role of vitamin D deficiency in neuromuscular disease.

**Table 1: Studies of vitamin D deficiency prevalence in healthy children and adolescents.**

| Study | Population characteristics | Location | Sample size | Vitamin deficiency prevalence* |
|-------|-----------------------------|----------|-------------|--------------------------------|
| Gordon et al. [38] | Adolescents (age 11-18 years) in urban area | USA | 307 | 42.00% |
| Gordon et al. [38] | Otherwise healthy infants and toddlers (age 8-24 months) in urban area | USA | 380 | 12.10% |
| Andiran et al. [39] | Children and adolescents (age 0-16 years) | Turkey | 440 | 40% |
| Zhu et al. [35] | Children and adolescents (age 0-16 years) subdivided into age groups | China | 2116 (age 0-1) | 5.40% |
| | | | 2269 (age 2-5) | 21.90% |
| | | | 1440 (age 6-11) | 40.40% |
| | | | 183 (age 12-16) | 46.40% |

*Deficiency defined as <50 nmol/L or <20 ng/mL 25-hydroxyvitamin D

**Table 2: Recommended treatment protocol for vitamin D deficiency in children [18].**

| Age | Acute treatment |
|-----|-----------------|
| <1 month | 1000 IU/day vitamin D for 3 months |
| 1-12 months | 3000 IU/day vitamin D for 3 months OR 300,000 IU over 1-7 days |
| >12 months | 5000 IU/day vitamin D for 3 months OR 500,000 IU over 1-7 days |

**Management of Vitamin D Deficiency**

Children at risk of vitamin D deficiency or who already suffer from deficiency may be treated with vitamin D supplements. Both the American Academy of Pediatrics and an Australian consensus statement recommend that children who are in at-risk groups or who do not have the recommended daily intake of 400 IU of vitamin D should receive a vitamin D supplement of 400 IU/day [18,19].
Methods for treating established vitamin D deficiency in children vary, but an Australian consensus statement recommends daily supplementation of between 1,000-5,000 IU vitamin D for 3 months (Table 2) [19]. High-dose stoss therapy, in which the total treatment dose of vitamin D (300,000-500,000 IU) is administered over 1-4 doses, has also been shown to be effective in treating vitamin D deficiency, although the best protocol has yet to be determined [19,42,43]. Calcium should be monitored and supplemented if low, and maintenance supplementation of 400 IU/day vitamin D should be continued after treatment [19].

**Duchenne Muscular Dystrophy**

Duchenne Muscular Dystrophy (DMD) is an X-linked recessive disease affecting about 1 in 3600 to 6000 live male births, usually diagnosed at about 5 years of age [44,45]. The disease is caused by a mutation in the dystrophin gene which results in the absence or defect of dystrophin proteins and the consequent instability and degeneration of muscle fibres [46]. This leads to progressive muscle weakness, loss of independent ambulation by about 13 years of age, and premature death [47,48].

**Bone Health Issues in DMD**

Boys with DMD possess several major risk factors for poor bone health, including reduced weight-bearing exercise, delayed puberty, side effects of treatment with corticosteroids, reduced mobility and consequently the potential for reduced exposure to sunlight, and pathological effects of the disease itself [49-51].

Disturbances in bone health are evident in boys with DMD prior to their decline in mobility, related to their progressive muscle weakness [52,53]. The reduction in weight-bearing activity due to this weakness directly hampers bone mass accrual, with a decline seen in both lower limb strength and BMC prior to loss of independent ambulation [24,54]. When independent ambulation is no longer possible, BMD decline is dramatically accelerated. Larson et al. [24] demonstrated that lumbar BMD dropped from a Z-score of -0.8 to -1.7 after the loss of ambulation, while BMD of the proximal femur dropped from -1.6 to a very low -3.9, increasing the risk particularly of long bone fracture. Without treatment, the majority of DMD patients are also at risk of developing severe scoliosis [55], which may require surgical stabilisation.

While corticosteroids (CS) are the standard therapy used to slow the progression of DMD, significantly prolonging ambulation, improving respiratory function and reducing the need for scoliosis surgery, the detrimental effect on bone mass may be profound [47,55]. BMD has been found to be considerably lower in CS-treated DMD patients than in steroid-naïve patients [53]. Studies have also demonstrated that CS therapy induces vertebral fractures in 19-38% of patients, which are very rare in steroid-naïve patients [55-57]. This may be partly accounted for by the protective effect of spinal surgery for scoliosis in steroid-naïve boys [49], but is difficult to ascertain. Delayed puberty, another side-effect of CS therapy, is an additional risk factor for poor bone health in this group [58]. It is clear that bone health protection in DMD warrants even greater attention due to the consequences of CS therapy, and studies are currently being undertaken to determine the best regimen of CS therapy which improves function while minimizing its negative impacts [49].

**Vitamin D Deficiency in DMD**

Vitamin D deficiency is another risk factor for poor bone health in DMD. While the prevalence of vitamin D deficiency in Australian DMD patients has not yet been established, remarkably only 22% of patients were vitamin D sufficient in a recent UK national audit [59]. Additional studies highlighting the frequency of vitamin D deficiency are summarised in Table 3. While correlations between low 25-OHD and low BMC have been found [58], little else is known about the association between vitamin D levels and bone health outcomes in DMD patients. This, and the prevalence of vitamin D deficiency in patients already prescribed supplements, is therefore areas in great need of further investigation.

| Study | Study Objective | Patient number | Vitamin D status | Mean spinal BMD Z-score | Prevalence of fractures | Study conclusion |
|-------|----------------|----------------|-----------------|------------------------|-------------------------|-----------------|
| Mayo et al. [60] | To compare changes in lumbar spine BMD with deflazacort therapy | 39 | - | -1 ± 1.3 before CS treatment, -3.6 ± 1.1 after 7-8 years of CS treatment | 21% (8) patients had long-bone fractures, 15% (6) patients had vertebral fractures | Patients on deflazacort therapy are at increased risk of vertebral fracture compared to steroid naïve patients, but not long-bone |
| Bianchi et al. [56] | To evaluate the effects of calcium and vitamin D supplementation on bone | 33 | 60.6% < 50 nmol/L | - | 21% (7) patients sustained fractures prior to enrolment | Vitamin D supplementation and adequate dietary calcium corrects vitamin D deficiency and increases BMC and BMD in most patients |
| Manzur et al. [57] | Audit on corticosteroid therapy, the prevalence of vitamin D deficiency, and vertebral fractures | 157 | 78% < 50 nmol/L prior to corticosteroid commencement | - | - | Data was used to inform workshop recommendations |
| Bianchi et al. [51] | To evaluate BMD and calcitropic hormones | 32 | Mean 13 nmol/L in CS-treated group, 35 nmol/L in non-CS-treated group | -3.9 ± 1.4 in CS-treated group, -2.6 ± 1.3 in non-CS-treated group | 18% (4/22) patients in CS-treated group and 20% (2/10) in non-CS-treated group sustained fractures | DMD patients experience decreased BMD and disturbed calcium metabolism, emphasized by CS therapy |
To examine BMD, bone turnover, body composition and calcitropic hormones

Mean 52 nmol/L

24% (6) patients sustained 11 fractures

DMD patients have reduced BMD and bone turnover, and interventions that increase bone formation should be considered

To assess the relationships between bone density, mobility, and fractures

44% (18) patients sustained fractures, 66% of which were in lower extremities

Low BMD is most profound in lower extremities and begins developing while still ambulating, which can result in fracture and early loss of ambulation

Table 3: Results of studies assessing bone health in Duchenne Muscular Dystrophy.

Figure 2: Recommendations for bone health assessment in DMD [51,52]. Regular assessment of bone health should be undertaken via serum 25-hydroxy vitamin D (25(OH) D) levels, monitoring of vitamin D and calcium intake and dual energy x-ray absorptiometry (DEXA) scans. Lateral spine radiographs should be performed in children at risk of vertebral fracture for consideration of bisphosphonate therapy. *Z-score adjusted for body size.

Fracture in DMD

Because of the risk factors discussed above, boys with DMD generally have significantly lower BMD than healthy controls and are more vulnerable to fractures and negative bone outcomes (Table 3) [52,53,60]. Studies have found that between 21-44% of DMD patients experience fractures [24,61], which are generally long-bone in younger, ambulatory boys, and vertebral in older, non-ambulatory patients who have several years of corticosteroid therapy and significantly lower BMD [62]. These rates of fracture are considerably higher than the prevalence of fracture found in a large healthy cohort of children (8.9%) [30], suggesting that the reduced BMD of DMD patients are linked to increased fracture risk. However, just as there is difficulty ascertaining an accurate relationship between BMD Z-scores and fracture risk in healthy children, limited sample sizes in DMD studies mean that even less is known in this population.

As well as being painful, fractures in DMD have a significant impact on mobility. Prolonged immobilisation after a fracture can lead to the deterioration of muscle strength, with 20-44% of fractures resulting in the permanent loss of ambulation in previously walking patients [24,58,61]. Due to the positive effects of prolonged ambulation on quality of life in DMD, the development of strategies to optimise bone health and prevent fractures are consequently of great importance.

Assessment of Bone Health in DMD

While the need for assessment and management strategies for the protection of bone health in DMD is critical given the factors discussed above, there is currently no international consensus on this issue. However, several workshops have convened to develop recommendations for bone assessment and management, as summarised in Figure 2.

Despite the development of these guidelines, numerous areas of uncertainty exist. As previously discussed, bone assessments are very challenging to interpret even in healthy children, and DMD patients pose even greater challenges. The delayed growth and puberty and decreased muscle mass seen in DMD can skew DXA readings and bone turnover markers, emphasised further by corticosteroid use [50]. Although a few studies have evaluated bone turnover markers in DMD patients [52,53], these have produced inconsistent results. There is consequently little data which can be used to help prevent and predict fractures in DMD. Contractures and poor mobility also create...
practical difficulties in performing DXA scans in more severe patients. Hence, while it is clearly important to monitor bone health in DMD, it is difficult to accurately do so.

**Illustrative Case Study**

The following case highlights the bone-related complications that can occur in DMD and assessment approach. A 12 year old boy with DMD presented with back pain during his regular check-up at the neuromuscular clinic. He had experienced intermittent lower back pain for the last 2 months, which had intensified after a fall 1 month previously. Despite still being capable of ambulation, the patient now preferred to use his wheelchair due to the severity of his back pain. He had been taking 2 paracetamol tablets daily to relieve the pain.

The patient had been treated with prednisone since the age of 5 to slow rate of decline of muscle strength. He was distinctly Cushingoid, with short stature, delayed puberty and obesity (weight 50.6 kg, height 1.2 m and BMI 35.2). He had a past history of moderate vitamin D insufficiency, with his lowest recorded 25-OHD level being 30 nmol/L. In response, he had been prescribed 1000 IU of vitamin D supplementation for 3 years and had also received stoss therapy. His most recent 25-OHD was sufficient at 78 nmol/L, which was measured at the time of his presentation with back pain.

He was distinctively Cushingoid, with short stature, delayed puberty and obesity (weight 50.6 kg, height 1.2 m and BMI 35.2). He had a past history of moderate vitamin D insufficiency, with his lowest recorded 25-OHD level being 30 nmol/L. In response, he had been prescribed 1000 IU of vitamin D supplementation for 3 years and had also received stoss therapy. His most recent 25-OHD was sufficient at 78 nmol/L, which was measured at the time of his presentation with back pain.

Management of Bone Health in DMD

Current management of DMD bone health focuses on maximising bone mineralisation to prevent future fractures. Hence, it is important to ensure that dietary intake contains adequate calcium and is supplemented if necessary, and that adequate sunlight exposure is encouraged to maintain vitamin D levels. It is also recommended that patients receive a daily vitamin D supplement during corticosteroid therapy [48,63]. This has shown to be effective in treating vitamin D deficiency in DMD patients, with a study by Bianchi et al. [58] demonstrating that vitamin D supplementation over 2 years significantly increased mean 25-OHD levels from <50 nmol/L to well within the normal range. However, the optimum amount of supplementation has not yet been established due to the lack and variable design of studies in DMD patients. Similarly, while the importance of physical activity in improving bone health is understood, it is not completely known what the best level of activity is to prevent acceleration of muscle degeneration. It is currently recommended that exercise be submaximal, with care taken to avoid overexertion [48].

Bisphosphonates are the standard therapy used to treat osteoporosis in adults due to their ability to reduce bone resorption. Although they have not yet been established as safe in paediatric populations, protocols are now evolving for their use in children with DMD [51]. Studies in children suffering from osteoporosis have shown that intravenous bisphosphonates are well-tolerated except for transient first-dose side effects, and that they are associated with improved BMD and skeletal architecture but significantly decreased bone turnover [64,65]. It was also recently shown that the use of intravenous bisphosphonates to treat vertebral fractures in DMD was associated with significant improvements in back pain and vertebral height, although they do not completely protect from further vertebral fracture [66]. Hence, it is currently recommended that intravenous bisphosphonate infusions are only provided to DMD patients who have sustained a vertebral fracture [48].

The use of oral bisphosphonates as a treatment or preventative therapy in DMD remains controversial. A Cochrane review of bisphosphonate therapy for secondary osteoporosis in children concluded that while short-term (<3 years) bisphosphonate use appeared well-tolerated, bisphosphonates as standard therapy was not justified [67]. However, small studies in DMD patients have demonstrated mainly positive results. Hawker et al. [68] found that daily administration of the oral bisphosphonate alendronate in a group of steroid-treated DMD patients had positive effects on BMD, particularly amongst younger children. However, while no vertebral fractures were reported in the 2 year trial period, there was insufficient data in this study to draw conclusions about the effects of bisphosphonates on fracture risk. A recent study also demonstrated that bisphosphonate therapy was significantly associated with increased survival in children with DMD [69]. Bisphosphonate therapy hence appears promising, but further research is required to determine whether long-term bisphosphonate therapy in DMD is beneficial in reducing the risk of fractures and to investigate optimal doses and regimens.

**Figure 3:** Lateral radiograph showing vertebral crush fractures to T9 and T10 in 12 year old DMD patient.
Conclusion

Patients with DMD are predisposed to poor bone health, making them vulnerable to osteoporosis and fracture. It is therefore crucial to develop strategies which protect and optimise bone health in these patients. Despite increasing recognition of this, the assessment and management of bone health in DMD clearly remains a challenge. Many areas of uncertainty still exist, and the optimal management and treatment of bone health and its complications is not yet established. Addressing modifiable bone health determinants such as vitamin D levels has great potential to improve bone health in DMD patients, and is hence an area that would greatly benefit from further research.

References

1. World Health Organisation (2004) Who scientific group on the assessment of osteoporosis at primary health care level.
2. Bachrach LK (2001) Acquisition of optimal bone mass in childhood and adolescence. Trends Endocrinol Metab 12: 22-28.
3. Heaney RP, Abrams S, Dawson-Hughes B, Looker A, Marcus R, et al. (2000) Peak bone mass. Osteoporos Int 11: 985-1009.
4. Henwood MJ, Binkovitz L (2009) Update on pediatric bone health. J Am Osteopath Assoc 109: 5-12.
5. Joyce NC, Hache LP, Clemens PR (2012) Bone health and associated metabolic complications in neuromuscular diseases. Phys Med Rehabil Clin N Am 23: 773-799.
6. Heaney RP (2007) Bone health. Am J Clin Nutr 85: 300S-303S.
7. DeLuca HF, Zierold C (1998) Mechanisms and functions of vitamin D. Nutr Rev 56: S4-S10.
8. Vanderschueren D, Vandenberg L, Boonen S, Lindberg MK, Bouillon R, et al. (2004) Androgens and bone. Endocr Rev 25: 389-425.
9. Singh D, Sanyal J, Chattopadhyay N (2011) The role of estrogen in bone growth and formation: Changes at puberty. Cell Heal Cytoskel 3: 2-12.
10. Riggs BL, Khosla S, Melton LJ 3rd (2000)Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int 11: 281-294.
11. Fewtrell MS, British Paediatric & Adolescent Bone Group (2003) Bone densitometry in children assessed by dual x ray absorptiometry: uses and pitfalls. Arch Dis Child 88: 795-798.
12. Gordon CM, Bachrach LK, Carpenter TO, Crabtree N, El-Hajj Fuleihan G, et al. (2008) Dual energy x-ray absorptiometry interpretation and reporting in children and adolescents: A Clin Densitom: Assessem Skel Heal 11: 43-58.
13. Clark EM, Ness AR, Bishop NJ, Tobias JH (2006) Association between bone mass and fractures in children: a prospective cohort study. J Bone Miner Res 21: 1489-1495.
14. Working Group of the Australian and New Zealand Bone and Mineral Society; Endocrine Society of Australia; Osteoporosis Australia (2005) Vitamin D and adult bone health in Australia and New Zealand: a position statement. Med J Aust 182: 281-285.
15. Holick MF (2006) Resurrection of vitamin D deficiency and rickets. J Clin Invest 116: 2062-2072.
16. Munns CF, Sinn PM, Rodda CP, Garnett SP, Zacharin MR, et al. (2012) Incidence of vitamin D deficiency rickets among Australian children: an Australian Paediatric Surveillance Unit study. Med J Aust 196: 466-468.
17. Ramagopalan SV, Heger A, Berlanga AJ, Mauer JJ, Lincoln MR, et al. (2010) A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res 20: 1352-1360.
18. Hossein-nezhad A, Spira A, Holick MF (2013) Influence of vitamin D status and vitamin D3 supplementation on genome wide expression of white blood cells: a randomized double-blind clinical trial. PLoS One 8: e58725.
19. Daly RM, Gagnon C, Lu ZX, Magliano DJ, Dunstan DW, et al. (2012) Prevalence of vitamin D deficiency and its determinants in Australian adults aged 25 years and older: a national, population-based study. Clin Endocrinol (Oxf) 77: 26-35.
20. Zhu Z, Zhan J, Shao J, Chen W, Chen L, et al. (2012) High prevalence of vitamin D deficiency among children aged 1 month to 16 years in Hangzhou, China. BMC Public Health 12: 126.
21. Forrest KY, Stuhldreher WL (2011) Prevalence and correlates of vitamin D deficiency in US adults. Nutr Res 31: 48-54.
22. Gordon CM, Feldman HA, Sinclair L, Williams AL, Kleinman PK, et al. (2008) Prevalence of vitamin D deficiency among healthy infants and toddlers. Arch Pediatr Adolesc Med 162: 505–512.
23. Gordon CM, DePeter KC, Feldman HA, Grace E, Emans SJ (2004) Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med 158: 531-537.
24. Andran N, Celik N, Akca H, Dogan G (2012) Vitamin D deficiency in children and adolescents. J Clin Res Pediatr Endocrinol 4: 25-29.
42. Huh SY, Gordon CM (2008) Vitamin D deficiency in children and adolescents: epidemiology, impact and treatment. Rev Endocr Metab Disord 9: 161-170.

43. Shah BR, Finberg I. (1994) Single-day therapy for nutritional vitamin D-deficiency rickets: a preferred method. J Pediatr 125: 487-490.

44. Emery AE (1991) Population frequencies of inherited neuromuscular diseases—a world survey. Neuromuscul Disord 1: 19-29.

45. Drousiotou A, Ioanou P, Georgiou T, Mavrikios E, Christopoulos G, et al. (1998) Neonatal screening for Duchenne muscular dystrophy: A novel semiquantitative application of the bioluminescence test for creatine kinase in a pilot national program in Cyprus. Genet Test 2: 55-60.

46. Hoffman EP, Brown RH Jr, Kunkel LM (1987) Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell 51: 919-928.

47. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, et al. (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9: 77-93.

48. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, et al. (2010) Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 9: 177-189.

49. Quinlivan R, Shaw N, Bushby K (2010) 170th ENMC International Workshop: bone protection for corticosteroid treated Duchenne muscular dystrophy. 27-29 November 2009, Naarden, The Netherlands. Neuromusc Disord 20: 761-769.

50. Biggar WD, Bachrach LK, Henderson RC, Kalkwarf H, Plotkin H, et al. (2005) Bone health in Duchenne muscular dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004. Neuromusc Disord 15: 80-85.

51. Bianchi ML, Biggar D, Bushby K, Rogol AD, Rutter MM, et al. (2011) Endocrine aspects of Duchenne muscular dystrophy. Neuromusc Disord 21: 298-303.

52. Söderpalm AC, Magnusson P, Ahlander AC, Karlsson J, Krokmark AK, et al. (2007) Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy. Neuromusc Disord 17: 919-928.

53. Bianchi ML, Mazzanti A, Galbiati E, Sarafooglou S, Dubini A, et al. (2003) Bone mineral density and bone metabolism in Duchenne muscular dystrophy. Osteoporos Int 14: 761-767.

54. Aparicio LF, Jurkovic M, DeLuollo J (2002) Decreased bone density in ambulatory patients with Duchenne muscular dystrophy. J Pediatr Orthop 22: 179-181.

55. King WM, Ruttencutter R, Nagaraja HN, Matkovic V, Landoll J, et al. (2007) Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 68: 1607-1613.

56. Houde S, Filiatraut M, Fournier A, Dubé J, D’Arcy S, et al. (2008) Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Pediatr Neurol 38: 200-206.

57. Balaban B, Matthews DJ, Clayton GH, Carry T (2005) Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: Long-term effect. Am J Phys Med Rehabil 84: 843-850.

58. Bianchi ML, Morandi L, Andreucci E, Vai S, Frasunkiewicz J, et al. (2011) Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: Response to calcium and vitamin D treatment. Osteoporos Int 22: 529-539.

59. Manzur AY, Scott E, Munot P, Vijay kumar K, Muntoni F, et al. (2010) National audit results in Duchenne muscular dystrophy (dmd) corticosteroid practice, vitamin D status and bone health. Neuro Musc Dis 20: 58.

60. Rufo A, Del Fattore A, Capulli M, Carvello F, De Pasquale L, et al. (2011) Mechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humans. J Bone Miner Res 26: 1891-1903.

61. McDonald DG, Kinali M, Gallagher AC, Mercuri E, Muntoni F, et al. (2002) Fracture prevalence in Duchenne muscular dystrophy. Dev Med Child Neurol 44: 695-698.

62. Mayo AL, Craven BC, McAdam LC, Biggar WD (2012) Bone health in boys with Duchenne Muscular Dystrophy on long-term daily deflazacort therapy. Neuromusc Disord 22: 1040-1045.

63. Davidson ZE, Truby H (2009) A review of nutrition in Duchenne muscular dystrophy. J Hum Nutr Diet 22: 383-393.

64. Simm PJ, Johannesen J, Briody J, McQuade M, Hsu B, et al. (2011) Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis. Bone 49: 939-943.

65. Munns CF, Rauch F, Travers R, Giorieux FH (2005) Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: Clinical and histomorphometric outcome. J Bone Miner Res 20: 1235-1243.

66. Shroccchi AM, Rauch F, Jacob P, McCormick A, McMillan HJ, et al. (2012) The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy. Osteoporos Int 23: 2703-2711.

67. Ward L, Tricco AC, Phuong P, Cranney A, Barrowman N, et al. (2007) Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev: CD005324.

68. Hawker GA, Ridout R, Harris VA, Chase CC, Fielding LJ, et al. (2005) Alendronate in the treatment of low bone mass in steroid-treated boys with Duchenne muscular dystrophy. Arch Phys Med Rehabil 86: 284-288.

69. Gordon KE, Dooley JM, Sheppard KM, MacSween J, Esser MJ (2011) Impact of bisphosphonates on survival for patients with Duchenne muscular dystrophy. Pediatrics 127: e353-358.